CJC-1295 DAC and No DAC

What’s the Difference Between CJC-1295 DAC and No DAC

CJC-1295 is a lab-engineered peptide that mimics growth hormone-releasing hormone, called GHRH. It has caught researchers’ attention for its ability to boost growth hormone (GH) production. This peptide exists in two main types: one includes the Drug Affinity Complex (DAC), and the other does not (No DAC). It’s essential to understand the differences between the CJC-1295 DAC and No DAC versions when comparing their uses and effectiveness.ย 

Structural Differences: Comparing CJC-1295 DAC and No DAC Versions

CJC-1295 Without DAC

CJC-1295 without DAC is an adjusted version of GRF (1-29), which is also called Sermorelin. Scientists changed it to make it more stable than the original GRF (1-29), but they did not include the Drug Affinity Complex. This variant of CJC-1295 has a short half-life that lasts between 30 minutes and an hour.

CJC-1295 With DAC

The version with DAC includes a drug affinity complex, changing how the peptide behaves in the body. This added component lets the peptide attach to albumin found in the body after itโ€™s been injected. This change extends its half-life to around 8 days, reducing the number of injections needed.

How CJC-1295 Works

CJC-1295 Without DAC

CJC-1295 without DAC works by boosting growth hormone release from the pituitary gland in pulses. This copies the way the body releases growth hormone. It connects to GHRH receptors in the pituitary gland after it is given, which causes growth hormone secretion. The pulse-like release is thought to have a benefit because it mirrors the normal GH release in the body.

CJC-1295 With DAC

While the core process stays the same, CJC-1295 with DAC leads to longer-lasting GH release because of its prolonged half-life. A study by Ionescu and Frohman in the Journal of Clinical Endocrinology & Metabolism showed that a single dose of CJC-1295 with DAC raised basal GH levels by 7.5 times and retained normal GH pulse patterns. This caused a 46% rise in average GH levels along with a 45% rise in IGF-1 (Insulin-like Growth Factor 1).

Benefits of CJC-1295

CJC-1295 With DAC

Clinical trials reveal several possible advantages of CJC-1295 with DAC:

Long-Term GH and IGF-I Increase: Researchers like Teichman and team conducted a placebo-controlled study showing that injecting CJC-1295 with DAC under the skin caused plasma GH levels to rise 2-10 times for at least six days. They also saw plasma IGF-I levels increase about 1.5-3 times for 9 to 11 days, even from just one dose.

  • Better muscle growth and repair: Higher GH and IGF-I levels aid in building muscles and fixing tissue damage.
  • Healthier body composition: These hormones assist in cutting down body fat while keeping or growing lean muscle.
  • Improved metabolic health: Sustained hormonal increase helps metabolism work better and improves energy use.

Extended Effects: The research revealed repeated doses could build up an impact, keeping IGF-I levels higher for as long as 28 days.

  • Ease of use: Effects can last as long as 28 days so users need injections less often than with other peptides.
  • Steady benefits: IGF-I levels stay elevated longer leading to more stable effects instead of sharp highs and lows.
  • More cost-efficient: Effects that last longer reduce the number of doses needed to keep benefits.

 

Maintained GH Pulsatility: The study by Ionescu and Frohman revealed that CJC-1295 with DAC boosted GH secretion and kept its natural pulsatility intact. This natural rhythm is thought to be essential to the hormone’s many physiological roles.

  • Receptor response: The natural pulses help stop receptors from becoming less responsive, which happens when hormones are always present.
  • Hormonal balance: Keeping the body’s rhythms steady ensures normal hormonal feedback stays on track.
  • Fewer side effects: Copying how the body works causes less disturbance to other hormones than just giving GH .

CJC-1295 Without DAC

This version offers similar benefits as above, but with more user advantages:

  1. Acts Like Natural GH Release: It triggers the release of growth hormone in bursts (pulsatile,) which may result in a pattern closer to how the body works.
  2. Adjustable Dosing: Its shorter half-life lets users adjust doses more based on their specific needs and how their body reacts.
  3. Fast Breakdown: The body processes it faster, which might lower the chances of side effects linked to extended high levels of growth hormone.

Safety and Side Effects of CJC-1295 DAC and No DAC

CJC-1295 With DAC

Teichman et al. conducted clinical trials where they found CJC-1295 with DAC to be โ€œsafe and relatively well tolerated,โ€ at 30 or 60 ฮผg/kg doses. During the 28 and 49-day study periods, no serious adverse effects appeared.

In clinical use, the usual side effects might include:

  • Reactions where the injection is given
  • Feeling dizzy
  • Headaches
  • Skin flushing
  • Brief numbness

CJC-1295 Without DAC

Because it remains active in the body for a shorter time, the version without DAC might show certain differences:

  • A reduced chance of lingering side effects
  • Any small chance of minimal side effects, such as headaches, is easier to handle because they fade faster
  • A lower risk of disrupting hormones due to the natural pulsatile pattern of GH release

Medical Uses and Important Points of CJC-1295 DAC and No DAC

The decision to use CJC-1295 with or without DAC depends on the intended treatment goals.

Why Choose CJC-1295 With DAC:

  • If fewer injections are preferred, like once a week or every two weeks
  • To achieve a steady rise in GH levels over time
  • When maintaining higher IGF-1 levels is a main treatment aim

Why Choose CJC-1295 Without DAC:

  • Use this when a natural pulsatile GH release is preferred
  • To treat patients who benefit more from occasional GH stimulation
  • When having a flexible dosing schedule matters
  • To help those who are more prone to side effects from long-term GH exposure

Dosing Guidelines

The varying half-lives of these peptides mean their administration needs differ:

CJC-1295 With DAC:

  • Administered around one to two times each week
  • Clinical studies have shown common doses between 30 and 60 ฮผg/kg

CJC-1295 No DAC:

  • Requires more frequent doses, sometimes several times a day
  • Dosing depends on how the patient responds

Final Thoughts of CJC-1295 DAC and No DAC

Each type of CJC-1295 has its own benefits and factors to think about. The DAC version makes things easier since it requires fewer doses and keeps hormone levels steady over time. On the other hand, the non-DAC version allows for a more natural release of growth hormone in pulses, which gives more control in how itโ€™s used.

Studies by Teichman, Ionescu, and Frohman show that CJC-1295 with DAC works well and is safe. Even though the non-DAC version hasnโ€™t been studied as much in detailed clinical trials, experts suggest it could have certain benefits in specific situations.

More studies are needed to assess the long-term effects and results of both forms of CJC-1295 in different groups and to achieve specific treatment goals.

You can purchase our CJC-1295 and Ipamorelin mix HERE.

References:ย 

Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse – PubMed

Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects – PubMed

Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults – PubMed

Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog – PubMed

Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog – PubMed

An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma – PubMed

Leave a Reply

Your email address will not be published. Required fields are marked *